Following the work by Cai et al., this review focuses on the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint and summarizes existing clinical evidence on the use of PD-(L)1 inhibitors in patients with cancer and select viral infections [26]. Here, PDCD1 is linked to cancer.